RATENT





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Michael HARTER, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2003/013433

Title: Isophtalic Acid Derivatives

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Tilman Breitenstein

Limited Recognition under 37 C.F.R. 11.9(b)

Agent for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 Telephone: (203) 812-2226 Facsimile: (203) 812-6459

Form PTC (Modified		U.S. Depa of Commerce Patent and demark Office						Serial No.	Art Unit	ing Date		Atty. Docket No. Le A 36 436		
INFORMATION DISCLOSURE CITATION							ΓΙΟΝ		Applicant(s)	JC09 Re Michael HART	C'd PCT/ ER, et al.	PTO 0	AUL E	200
			-				U.	S. PA	TENT DOCU	MENTS				
*	T	DOCUMENT NO.							DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	U1	2002/0045751					7 5 1	į.	04/18/02	Kukkola	540	607	09/28/01	
]	FORE	EIGN	PATENT DO	CUMENTS				
*		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSL	ATION NO
	F1	0	7	9	1	5	7	6	27/08/97	EP				
	F2	9	8	4	0	3	6	4	17/09/98	WO				
	F3	9	8	4	0	3	7	0	17/09/98	WO	· · · · · · · · · · · · · · · · · · ·			
									jj					co-icoo-i
2.32														
			OTH)	ER R	EFEI	RENC	CES (Inclu	ding Author, T	itle, Date, Pert	inent Pages	, etc.)		
						· · · · · ·								
		U.												
EXAMINI	ER								DATE	CONSIDERED				
									is in conformance value tion to applicant.	with MPEP 609. D	raw line throug	h citation if n	ot in confort	nance